CGT partnership to automate for greater patient accessibility 


ScaleReady and CTMC, a joint venture between National Resilience and MD Anderson Cancer Center, have partnered to help lessen the manufacturing barriers holding back life-saving cell and gene therapies (CGTs) from reaching more patients by integrating automation tools.  

The agreement will enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilising the Fresenius Kabi Lovo and Cue cell processing systems.  

“ScaleReady’s expertise and platform access will help us to leverage innovative technologies, like the Lovo, for our cell therapy process,” said Laine Linden, Head of CTMC Technical Operations. “With the addition of the Fresenius Kabi Cue to our manufacturing platform, we hope to drive down variability and increase the number of patients we can successfully treat by automating and closing the final fill and finish steps of our cell therapy products.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free